GSK's Lovaza faces generics after court invalidates Pronova patent
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's omega-3 fatty acid Lovaza and Amarin's Vascepa for the treatment of high triglycerides may face generic competition within the next few months after a US appeals court invalidated the last Pronova BioPharma patent protecting GSK's fish oil pill.